Navigation Links
Breast Cancer Drug Duo Wins Out in Study
Date:8/2/2012

By Kathleen Doheny
HealthDay Reporter

WEDNESDAY, Aug. 1 (HealthDay News) -- A combination of two cancer drugs works better than one alone to improve survival in older women with a type of breast cancer that has spread, new research suggests.

The drugs -- anastrozole (Arimidex) and fulvestrant (Faslodex) -- are currently used individually to treat breast cancer, said researcher Dr. Rita Mehta, an associate professor of health sciences at the University of California, Irvine, School of Medicine.

For the study, published Aug. 2 in the New England Journal of Medicine, about 700 postmenopausal women were assigned to Arimidex alone or to both drugs. Mehta looked at whether the combination improved their survival, and whether the cancer spread or not, which is termed progression-free survival.

"With the combination, there is a 20 percent improvement in progression-free survival and a 19 percent improvement in overall survival," Mehta said.

Put another way, those getting the combined treatment gained six months. They lived a median of 47.7 months (half lived longer, half less) while the solo-drug patients lived a median of 41.3 months.

The disease took 15 months to progress in the patients on both drugs, but just 13.5 on the solo drugs. Forty-one percent of the women taking Arimidex whose disease progressed later switched to Faslodex, which led the researchers to conclude that simultaneous treatment rather than sequential treatment brought about the benefits.

While other serious side effects were similar in both groups, three women in the combination-drug group died, which was possibly associated with the treatment.

The five-year study was supported by the U.S. National Cancer Institute and AstraZeneca Pharmaceuticals, which makes both drugs.

All the women had hormone receptor-positive breast cancer, which requires estrogen to grow and accounts for more than 50 percent of all cases of breast cancer.

Arimidex, which is given orally, works by reducing the amount of estrogen the body makes. Faslodex -- an injectable drug -- blocks the action of estrogen on cancer cells.

Previous studies of combination hormonal therapy have been unsuccessful, Mehta said. But she decided to look at this pair because of the complementary way in which these two drugs work.

The findings are solid, said Dr. Joanne Mortimer, director of the Women's Cancer Program at the City of Hope Comprehensive Cancer Center, in Duarte, Calif.

Although the study had drug company support, the company did not have input in conducting the study, she noted.

While the improvement in progression-free survival, 1.5 months, may not seem notable, the difference in overall survival is impressive, she said.

"Much more important to the patients is if they live longer," she said. ''Survival is the gold standard."

Adding Faslodex to Arimidex treatment would tack on about $700 a month, experts said. However, as both drugs are FDA-approved, insurance plans may cover the regimen. The dose of Faslodex used in this trial was less than the standard dose.

Several other regimens to help women with this form of breast cancer are under study, too, Mortimer said. "We are not sure how this [particular] combination will be incorporated into clinical practice," she said.

More information

To learn more about breast cancer, visit the U.S. National Library of Medicine.

SOURCES: Rita Mehta, M.D., associate professor, health sciences, University of California, Irvine, School of Medicine, and oncologist, Chao Family Comprehensive Cancer Center, Orange, Calif.; Joanne Mortimer, M.D., director, Women's Cancer Program, City of Hope Comprehensive Cancer Center, Duarte, Calif.; Aug. 2, 2012, New England Journal of Medicine


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Eliminating the good cholesterol receptor may fight breast cancer
2. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
3. Researchers develop a new cell and animal model of inflammatory breast cancer
4. Scientists uncover multiple faces of deadly breast cancer
5. Depo-Provera Birth Control Might Raise Breast Cancer Risk
6. Routine mammograms may result in significant overdiagnosis of invasive breast cancer
7. Mayo Clinic launches whole genome breast cancer study
8. Breast cancer patients suffer treatment-related side effects long after completing care
9. Teen Drinking May Boost Odds of Precancerous Breast Changes
10. Stress contributes to cognitive declines in women with breast cancer, researcher says
11. Breast Cancer Treatment Side Effects May Last for Years
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Breast Cancer Drug Duo Wins Out in Study
(Date:8/19/2017)... , ... August 18, 2017 , ... Western University of ... and education to launch the University’s new Center for Innovation on Wednesday, September 6, ... Education Center Lecture Hall 1, followed by a technology exhibition from 1 to 3 ...
(Date:8/19/2017)... York, New York (PRWEB) , ... August 19, ... ... Street Health has announced that it is the first organization with pending recognition ... CDC’s National Diabetes Prevention Program (“DPP”) via group telehealth classes and live video ...
(Date:8/19/2017)... CA (PRWEB) , ... August 19, 2017 , ... Yesterday, ... the KKK by saying there are two sides. There are not two sides to ... way to rationalize violence and prejudice, and the NPEIV stands against all forms of ...
(Date:8/19/2017)... ... ... “Congratulations! It's A Boy! God’s Gift: A Story of Love”: a children’s book ... A Boy! God’s Gift: A Story of Love” is the creation of published authors, ... by Christian Faith Publishing, Dale Anthony and Rachael Anthony’s new book is a perfect ...
(Date:8/18/2017)... ... ... ... For Immediate Release                Contact: Julian Teixeira, August ... Seek Sex and Relationship Advice from their Fathers , ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million and ... operations Second-quarter 2017 Branded ... Second-quarter 2017 Sterile Injectables ... Second-quarter 2017 adjusted diluted earnings per ... $0.93 Second-quarter 2017 reported ...
(Date:8/7/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent ... 30, 2017.  All comparisons, unless otherwise noted, are to the ... Second Quarter 2017 Highlights include: ... increase of 3.5% Total prescriptions dispensed of ... 7.5% versus 7.6% Gross profit per ...
(Date:8/3/2017)...  Opioid addiction and other drugs of abuse, blood ... threatening outcomes, were problems taken on directly as laboratory ... support them, met this week. This according to Kalorama ... of abuse, procalcitonin and acute kidney injury were key ... meeting in San Diego, CA. ...
Breaking Medicine Technology: